Infusion Nursing Notes Blog | All posts tagged 'CIDP'

HYQVIA® 10% — Learn About Expanded FDA-Approval for Treating PIDD and CIDP

23. May 2025 Marianna Herrera Nursing Support (0)

HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] Solution, for subcutaneous administration was first FDA-approved in 2014 for primary immunodeficiency (PIDD) in adults. In 2023, HYQVIA® received expanded FDA-approval in PIDD to include pediatric patients aged 2-16. In 2024 HYQVIA® received FDA-approval for maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP). [More]

Weaning IVIG Therapy for CIDP

15. July 2014 Michelle Greer (1)

Previously we began discussing how to wean patients with CIDP off IVIg therapy. In this week’s blog, we address common fears and questions. As well as when and how to implement a tapering plan. [More]

Understanding Immune or Inflammatory Neuropathy

28. January 2014 Jonathan Katz & Michelle Greer (1)

Certain neuropathies are characterized by conditions in which nerves are “attacked” by the patient’s own immune system. This blog explores common symptoms and treatment plans for these conditions. [More]

Autoimmune Motor Neuropathies

26. November 2013 Michael Weiss (1)

Some neuropathies may be autoimmune and others are not, and this will dictate the treatment. Understanding the various symptoms and diagnoses can help patients and practitioners. [More]

COVID 19 Pre-Visit Screen • Nursing Visit Guidance

Infusion Nursing Notes by Nufactor provides education, resources and support to promote successful patient therapy within the infusion nursing community.

HYQVIA® 10% — Learn About Expanded FDA-Approval for Treating PIDD and CIDP

Weaning IVIG Therapy for CIDP

Understanding Immune or Inflammatory Neuropathy

Autoimmune Motor Neuropathies

Payers

Support

About Us

Nufactor